Navigation Links
DRAXIS Responds to Trading
Date:3/17/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...have long suspected that sunlight has powerful -- ...endency to develop // a variety of diseases. The b... skin cancer. However, many suspect sunshine can h...n affect susceptibility to a variety of everyday v...
...al cancer is the second leading cause of cancer de...en detected at advanced stages. // Screening reduc...e more curable. A new study shows primary care pr...nts for colorectal cancer. Researchers attribute t...
... a recent study , Asian investigators suggest phys...because of its adverse effects.// A therapy routi... lung disease may result in slower neuromotor and ...ious research shows dexamethasone, a drug known as...
...arch shows scientific evidence that mental stress ...hmias are disturbances // in normal heart rhythm. ... while patients were under mental and physical str...risk for arrhythmias and healthy patients. For the...
Other Medicine News:Health News:Soaking In The Sun May Give You More Than Just a Tan 2
(Date:9/4/2008)...wswire/ -- Southern Research Institute,today annou...has selected,the organization to participate in th...n Center Network (MLPCN). The MLPCN -- a collabora...Libraries Program which is,designed to benefit hum...an,genome and validate future targets for drug dis...
(Date:9/4/2008)...4 /- Axentis Pharma AG has,initiated ...d tolerability,of a new therapeutic formulation fo...ystic fibrosis patients. The new formulation allow... directly to the site of,infection. The forthcomin...rent doses of the new drug. Initial results are ex...
(Date:9/4/2008)... antiviral activity and favorable safety ... Sept. 4 /- Idenix,Pharmace...l company engaged,in the discovery and development...er infectious diseases, today announced that it ha...IDX899, a non-nucleoside reverse,transcriptase inh...
(Date:9/4/2008)...edule with Two Abstracts Accepted for Presenta...2008, BRIDGEWATER, N.J., Sept. 4 /- ...ceutical company focused on the treatment of,cardi...he appointment of,Peter L. Garrambone, Jr. to the ... career includes more than 50 pharmaceutical,trans...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Inverness Medical Innovations to Participate at Morgan Stanley Global Healthcare Unplugged Conference on April 30 2008 4886 1Bypassing the insulin highway 3061 1FDA Examines Quality of Life for LASIK Patients 17784 1FDA Examines Quality of Life for LASIK Patients 17784 2FDA Examines Quality of Life for LASIK Patients 17784 3Engaging Health Care Consumers Online is Top Priority 17780 1Engaging Health Care Consumers Online is Top Priority 17780 2Engaging Health Care Consumers Online is Top Priority 17780 3
...eet Primary Endpoint of Improvement in Overall,Sur...re-FirstCall/ --,Allos Therapeutics, Inc. today an...s pivotal Phase 3 study of Efaproxyn ,(efaproxiral...en,with brain metastases originating from breast c...point of demonstrating a,statistically significant...
... 20, 2007 /PRNewswire-FirstCall/ -- Anadys,Pharmac...tted to,the discovery, development and commerciali...atitis and cancer, announced today that it,has nom...ent as an,orally-administered direct antiviral for...infection. , "We have identified a small-molecule,...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
The Infinity™ ALT single liquid stable reagent is intended for the in vitro quantitative determination of ALT in serum. , Infinity™ ALT reagent patented formulation not only provides ex
... analyzer. It is designed with the customer's anal...types of clinical chemistry tests, specific protei...tests, electrolytes and other user-definable appli...uitable for specialized chemistry applications out...
Inquire
ISI offers instrument cleaning brushes in a variety of lengths, diameters and composition. The long, thin brushes are perfect for cannulas and tubing. The smallest brushes are the answer for micros.
Medicine Products: